SecBot SecBot
8-K ·Filed May 1, 2026

PDSB

PDS Biotechnology Corp
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001140361-26-018464
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The refinancing and ATM facility underscore persistent cash burn. Watch for ATM issuances post-closing, which will dilute existing shareholders. Monitor preclinical/clinical catalysts to offset dilution; the stock may face near-term pressure as the market prices in the convertible note's discount features and potential registration of warrant shares.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9810
T+0 close · May 1, 2026 · via day close
Latest settled
−29.60%
T+60 · $0.6906
Vs SPY
−32.67%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $0.9810entry
  2. T+1 · 7mo ago +1.94%α +2.28% · $1.00
  3. T+5 · 6mo ago +16.21%α +13.86% · $1.14
  4. T+20 · 6mo ago +16.21%α +10.92% · $1.14
  5. T+60 · 4mo ago −29.60%α −32.67% · $0.6906
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology entered a $6M promissory note with YA II PN, LTD (10% interest, 12-month maturity) and issued a warrant for 2.16M shares at $1.1824, while prepaying existing convertible debentures at 103% of principal and terminating the prior ATM agreement. A new ATM facility with Yorkville Securities was also established. This financing, following a recently effective $200M S-3 shelf, signals urgent capital needs and potential dilution, weighing on the stock.

Key Financial Metrics

Deal Value
$6.0M
Deal Type
credit_facility
Offering Size
$6.0M

Key Facts

  • $6M promissory note at 10% interest, issued at $5.76M (4% OID), due 12 months from closing
  • Warrant to purchase 2,158,274 shares at $1.1824 per share (exercisable 6 months post-closing, 5-year term)
  • Prepayment of existing Senior Secured Convertible Debentures at 103% of principal plus accrued interest
  • New ATM sales agreement with Yorkville Securities under the effective S-3 shelf (up to $200M)
  • S-3/A shelf registration filed April 27, 2026, declared effective April 28, 2026
  • Closing expected on or around June 12, 2026, subject to conditions including repayment of existing debt

Financial Impact

$6M principal (4% OID), warrant representing ~4.1% of current shares outstanding (based on 52.6M shares outstanding estimate from market cap $53M at ~$1.01/share)

dilutiondebtliquidity

Risk Factors

  • Dilution from warrant exercise and potential conversion of the note (up to 19.99% of outstanding without stockholder approval)
  • Note conversion triggers after default (95% of 5-day VWAP or 92% of prior close) could lead to severe dilution if stock declines
  • ATM program may be used aggressively, further pressuring share price
  • Failure to meet closing conditions (e.g., debt repayment, Nasdaq listing) could disrupt financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-018464
Document: 0001140361-26-018464-index-headers.html0001140361-26-018464
Document: 0001140361-26-018464-index.html0001140361-26-018464
Document: 0001140361-26-018464.txt0001140361-26-018464

Track record

28 reports on PDSB

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 1, 2026